PCSK9 and familial hypercholesterolemia: Wasserman's focused on evolocumab (AMG145) for lipid-lowering, a PCSK9 inhibitor, as well as its efficacy and safety for cardiovascular events and PCSK9 in familial hypercholesterolemia.